•Senior's Center Home
•Back to Article
In This Report
•Highlights
•Introduction
•Causes
•Risk Factors
•Complications
•Symptoms
•Diagnosis
•Treatment
•Medications
•Surgery and Devices
•Lifestyle Changes
•Resources
•References
More Features
•Printer-friendly version

Heart failure - InDepth

Highlights

Heart failure is a condition in which the heart does not pump enough blood to meet the needs of the body's tissues. It can have a number of causes. Heart failure can develop slowly over time as the result of other conditions (such as high blood pressure and coronary artery disease) that weaken the heart. It can also occur suddenly as the result of damage to the heart muscle or a valve problem.

Common signs and symptoms of heart failure include:

Treatment for heart failure depends on its severity. All patients need dietary salt restriction and other lifestyle adjustments, medication, and monitoring. People with severe heart failure may need implanted devices (such as pacemakers, implantable cardiac defibrillators, or devices that help the heart pump blood) or surgery, including heart transplantation.

Doctors usually treat heart failure, and the underlying conditions that cause it, with a combination of medications. Some of these medications include:

Not all patients will be placed on all these medications. But most of them will be prescribed at least for some of the patients.

Three newer drugs are now available for select patients with heart failure:

For patients with advanced heart failure, symptom relief, quality of life, and personal values are as important to consider as survival, advises the American Heart Association (AHA). The AHA notes that while technology has increased the treatment options for advanced heart failure, "doing everything is not always the right thing." AHA guidelines emphasize a patient-centered approach to treatment and the importance of patients discussing with their doctors their preferences, expectations, and goals.

Introduction

Heart failure is a condition in which the heart does not pump enough blood to meet the needs of the body's tissues. To understand what occurs in heart failure, it helps to understand the anatomy of the heart and how it works.

The heart is composed of two independent pumping systems, one on the right side, and the other on the left. Each has two chambers, an atrium and a ventricle. The ventricles are the major pumps in the heart.

Heart - front view

The structures of the heart include the ventricles, atria, arteries, and veins. Arteries carry blood away from the heart while veins carry blood into the heart. The vessels colored blue indicates the transport of blood with relatively low content of oxygen and high content of carbon dioxide. The vessels colored red indicates the transport of blood with relatively high content of oxygen and low content of carbon dioxide.

The Right Side of the Heart

The right system receives blood from the veins of the whole body. This is "used" blood, which is poor in oxygen and rich in carbon dioxide. In the right side of the heart:

The Left Side of the Heart

The left system receives blood from the lungs. This blood is now rich in oxygen. In the left side of the heart:

The Valves

Valves are muscular flaps that open and close so that blood will flow in the right direction. There are four valves in the heart:

Heart - section through the middle

Click the icon to see an image of the heart through the middle.

Heartbeats are triggered and regulated by the conducting system, a network of specialized muscle cells that form a type of electrical system in the heart muscles. These cells are connected by channels that pass chemically-triggered electrical impulses.

Conduction system of the heart

Click the icon to see an image of the conduction system of the heart.

Heart failure is a clinical syndrome, not a single disease. The heart doesn't "fail" in the sense of ceasing to beat (as occurs during cardiac arrest). Rather, inefficient pumping can be caused by a number of factors.

In classic heart failure, the heart muscle weakens, sometimes acutely (as with a big heart attack) or it weakens over the course of months or years, so that it is unable to pump out enough of the blood that enters its chambers. As a result, fluids build up in the lungs and tissues, causing congestion. This is why heart failure is also sometimes referred to as "congestive heart failure." Other abnormalities can also cause heart failure. Some of them will be described below.

Ways the Heart Can Fail

Heart failure can occur in several ways:

Heart valves

Click the icon to see an image of heart valves.

Heart failure's specific effects on the body depend on whether it occurs on the left or right sides of the heart. Over time, in either form of heart failure, the organs in the body do not receive enough oxygen and nutrients, and the body's wastes are removed slowly. Eventually, vital systems break down.

Failure on the Left Side (Left-Ventricular Heart Failure)

Failure on the left side of the heart is more commonly recognized than failure on the right side. The failure can be a result of abnormal systolic (contraction) or diastolic (relaxation) action:

Ejection Fraction

To help characterize the left-sided heart failure, doctors use an ejection fraction (EF) calculation, also called a left-ventricular ejection fraction (LVEF). This is the percentage of the blood pumped out from the left ventricle during each heartbeat. An EF of 50% to 75% or so is considered normal. People with left-ventricular heart failure are classified as either having a preserved EF (greater than 40-50%) or a reduced EF (less than 40-50%).

People with preserved LVEF heart failure are more likely to be female, older, and have a history of high blood pressure and atrial fibrillation (a disturbance in heart rhythm). They may also have some of the other risk factors listed above.

Failure on the Right Side (Right-Ventricular Heart Failure)

Failure on the right side of the heart is most often a result of failure on the left. Because the right ventricle receives blood from the veins, failure here causes the blood to back up. As a result, the veins surrounding the heart fill up with blood and fluid. This fluid is pushed out into the body's tissues and causes swelling in the feet, ankles, legs, and abdomen. Pulmonary hypertension (increase in pressure in the lung's pulmonary artery) and lung disease may also cause right-sided heart failure.

Causes

Heart failure has many causes and can evolve in different ways.

In all cases, the weaker pumping action of the heart means that less blood is sent to the kidneys. The kidneys respond by retaining salt and water. This in turn increases edema (fluid buildup) in the body, which causes widespread damage.

Uncontrolled high blood pressure (hypertension) is a major cause of heart failure even in the absence of a heart attack. In fact, about 75% of cases of heart failure start with hypertension. It generally develops as follows:

Hypertension

Hypertension is a disorder characterized by consistently high blood pressure. In adults, high blood pressure is diagnosed when the systolic blood pressure (the "top" number, which represents the pressure generated when the heart beats) is 130 or higher or the diastolic blood pressure (the "bottom" number, which represents the pressure in the vessels when the heart is at rest) is 80 or higher.

Coronary artery disease is the result of a process called atherosclerosis (commonly called "hardening of the arteries"). It is the most common cause of heart attack and involves the buildup of cholesterol in the arteries, with inflammation and injury in the cells of the blood vessels. The arteries narrow and become brittle. Heart failure in such cases most often results from a pumping defect in the left side of the heart. But both sides can be affected.

Atherosclerosis

Click the icon to see an image of atherosclerosis.

People often survive heart attacks. But many eventually develop heart failure from the damage the attack does to the heart muscles.

The valves of the heart control the flow of blood leaving and entering the heart. Abnormalities can make it more difficult to get through a valve (stenosis) or cause blood to leak back through a valve (regurgitation or leaking).

Heart valves - superior view

Click the icon to see an image of heart valves - superior view.

In the past, rheumatic fever, which scars the heart valves and prevents them from functioning properly, was a major cause of death from heart failure. Fortunately, antibiotics and other advances have now made this disease a minor cause of heart failure in industrialized nations. Birth defects may also cause abnormal valvular development. Although more children born with heart defects are now living to adulthood, they still face a higher than average risk for heart failure as they age.

Cardiomyopathy is a disorder in which something has made the heart muscle abnormal and weakened, generally resulting in heart failure. There are several different types of cardiomyopathy. Injury to the heart muscles may cause the heart muscles to thin out (dilate) or become too thick (become hypertrophic). In either case, the heart doesn't pump correctly. A viral infection involving the heart muscle (viral myocarditis) is a rare viral infection that involves the heart muscle and can produce either temporary or permanent heart muscle damage.

Dilated Cardiomyopathy

Dilated cardiomyopathy involves an enlarged heart ventricle. The muscles thin out, reducing the heart's pumping action, usually on the left side. Although this condition is associated with genetic factors, the direct cause is often not known. (This is called idiopathic dilated cardiomyopathy.) In other cases, heart attacks, viral infections, alcoholism or other toxins, or long term, untreated high blood pressure may result in a dilated, dysfunctional heart.

Hypertrophic Cardiomyopathy

In hypertrophic cardiomyopathy, the heart muscles become thick, which can cause mechanical and electrical problems in the heart. Sometimes the walls of the heart become so thick that blood has difficulty being ejected from the heart. People may be at risk for sudden, deadly arrhythmias because of abnormalities in the conduction system. Hypertrophic cardiomyopathy may be due to a genetic defect that causes abnormalities in the heart muscle cells themselves. This condition occurs in about 1:500 people in the general population and is often the cause of sudden death in young athletes.

Hypertrophic cardiomyopathy

Click the icon to see an image of hypertrophic cardiomyopathy.

Restrictive Cardiomyopathy

Restrictive cardiomyopathy refers to a group of disorders in which the heart chambers are unable to properly fill with blood because of extreme stiffness in the heart. The heart is of normal size or only slightly enlarged. However, it cannot relax normally during the time between heartbeats when the blood returns from the body to the heart (diastole). The most common causes of restrictive cardiomyopathy are amyloidosis and scarring of the heart from an unknown cause (idiopathic myocardial fibrosis). It may occur after heart transplant.

Chronic obstructive pulmonary disease (COPD, a disease characterized by severe chronic bronchitis or emphysema) and other major lung diseases are risk factors for right-sided heart failure. Pulmonary hypertension is increased pressure in the pulmonary arteries that carry blood from the right side of the heart to the lungs. The increased pressure makes the heart work harder to pump blood, which can cause heart failure.

An overactive thyroid (hyperthyroidism) or underactive thyroid (hypothyroidism) can have severe effects on the heart and increase the risk for heart failure.

Risk Factors

Coronary artery disease, heart attack, and high blood pressure are the main causes and risk factors of heart failure. Other diseases that damage or weaken the heart muscle or heart valves can also cause heart failure. Heart failure is most common in people over age 65, African-Americans, and women.

Heart failure risk increases with advancing age. Heart failure is the most common reason for hospitalization in people age 65 years and older.

Men are at higher risk for heart failure than women. However, women are more likely than men to develop diastolic heart failure (a failure of the heart muscle to relax normally).

African-Americans are more likely than white people to develop heart failure before age 50 and die from the condition.

People with a family history of cardiomyopathies (diseases that damage the heart muscle) are at increased risk of developing heart failure. Researchers are investigating specific genetic variants that increase heart failure risk.

People with diabetes are at high risk for heart failure, particularly if they also have coronary artery disease and high blood pressure. Some types of diabetes medications, such as rosiglitazone (Avandia) and pioglitazone (Actos), may cause or worsen heart failure. Chronic kidney disease caused by diabetes also increases heart failure risk.

Obesity is associated with high blood pressure, high cholesterol levels, and type 2 diabetes, conditions that place people at risk for heart failure. Evidence strongly suggests that obesity itself is a major risk factor for heart failure, particularly in women.

Smoking, sedentary lifestyle, and alcohol and drug abuse can increase the risk for developing heart failure.

Certain drugs can potentially damage the heart and increase the risk for heart failure. Long-term use of high-dose anabolic steroids (male hormones used to build muscle mass) increases the risk for heart failure. The cancer drug imatinib (Gleevec) has rarely been associated with heart failure. Other chemotherapy drugs, such as doxorubicin (Adriamycin), can increase the risk for developing heart failure years after cancer treatment.

Cancer radiotherapy to the chest also increases the risk for heart disease and heart failure.

Complications

The complications caused by heart failure influence a patient's chance for survival. Although heart failure produces very high mortality rates, treatment advances are improving survival rates.

Cardiac Cachexia

If patients with heart failure are overweight to begin with, their condition tends to be more severe. Once heart failure develops, an important indicator of a worsening condition is the occurrence of cardiac cachexia, which is unintentional rapid weight loss (a loss of at least 7.5% of normal weight within 6 months).

Impaired Kidney Function

Heart failure weakens the heart's ability to pump blood. This can affect other parts of the body including the kidneys (which in turn can lead to fluid buildup). Decreased kidney function is common in patients with heart failure, both as a complication of heart failure and other diseases associated with heart failure (such as diabetes). This can be called the "cardio-renal syndrome." Studies suggest that, in patients with heart failure, impaired kidney function increases the risks for heart complications, hospitalization, and death.

Congestion (Fluid Buildup)

In left-sided heart failure, fluid builds up first in the lungs, a condition called pulmonary edema. Later, as right-sided heart failure develops, fluid builds up in the legs, feet, and abdomen. Fluid buildup is treated with lifestyle measures, such as reducing salt in the diet, as well as drugs, such as diuretics.

Arrhythmias (Irregular Beatings of the Heart)

There are several types of arrhythmias:

Angina and Heart Attacks

While coronary artery disease is a major cause of heart failure, people with heart failure are at continued risk for angina and heart attacks. Special care should be taken with sudden and strenuous exertion, particularly during colder months, with activities such as snow shoveling.

Symptoms

Many symptoms of heart failure result from the congestion that develops as fluid backs up into the lungs and leaks into the tissues. Other symptoms result from inadequate delivery of oxygen-rich blood to the body's tissues. Since heart failure can progress rapidly, it is essential to consult a doctor immediately if any of the following symptoms are detected:

Fatigue

Patients may feel unusually tired.

Shortness of Breath (Dyspnea)

Symptoms and types of dyspnea include:

Fluid Retention (Edema) and Weight Gain

Heart failure can cause foot, ankle, leg, or abdominal swelling. In rare cases, swelling can occur in the veins of the neck. Fluid retention can cause sudden weight gain and frequent urination.

Wheezing or Cough

Heart failure can cause asthma-like wheezing, or a dry hacking cough that occurs a few hours after lying down and stops after sitting up.

Loss of Muscle Mass

Over time, patients may lose muscle weight due to low cardiac output and a significant reduction in physical activity.

Gastrointestinal Symptoms

Problems include loss of appetite or a sense of feeling full after eating small amounts. People may also have abdominal pain.

Pulmonary Edema

When fluid in the lungs builds up, it is called pulmonary edema, which produces severe symptoms. These symptoms may develop suddenly or gradually build up over a matter of days:

Abnormal Heart Rhythms

Heart failure can cause episodes of abnormally fast or slow heart rate. People may need to have a pacemaker or defibrillator implanted.

Central Sleep Apnea

This sleep disorder results when the brain fails to signal the muscles to breathe during sleep. It occurs in up to half of people with heart failure. Sleep apnea causes disordered breathing at night. If heart failure progresses, the apnea may be so acute that a person, unable to breathe, may awaken from sleep in panic. Treatment with continuous positive airway pressure (CPAP) can be beneficial for people with heart failure and sleep apnea.

Diagnosis

Doctors can often make a preliminary diagnosis of heart failure by medical history and careful physical examination.

A thorough medical history may identify risks for heart failure that include:

The following physical signs, along with medical history, strongly suggest heart failure:

Both blood and urine tests are used to check for problems with the liver and kidneys and to detect signs of diabetes. Lab tests can include:

An electrocardiogram (ECG) is a test that measures and records the electrical activity of the heart. It is also called an EKG. An ECG cannot diagnose heart failure. But it may indicate underlying heart problems. The test is simple and painless to perform. It may be used to diagnose:

ECG

The electrocardiogram (ECG, EKG) is used extensively to diagnose heart disease, from congenital heart disease in infants to myocardial infarction and myocarditis in adults. There are several different types of electrocardiograms.

The best diagnostic test for heart failure is echocardiography. Echocardiography is a noninvasive test that uses ultrasound to image the heart as it is beating. Cardiac ultrasounds provide the following information:

Doctors use information from the echocardiogram for calculating the EF (ejection fraction, a measurement of how much blood is pumped out during each heartbeat), which is important for diagnosing heart failure and determining its severity. Stress echocardiography may be needed if coronary artery disease is suspected.

Doctors may recommend angiography if they suspect that blockage of the coronary arteries is contributing to heart failure. This procedure is invasive.

Cardiac catheterization

Click the icon to see an image of cardiac catheterization.

Radionuclide Ventriculography

Radionuclide ventriculography is an imaging technique that uses a tiny amount of radioactive material (called a trace element). It is very sensitive in revealing heart enlargement or evidence of fluid accumulation around the heart and lungs. It is an accurate way to measure the EF, although an echocardiogram is a much more common way to do this.

Chest x-rays can show whether the heart is enlarged. Computed tomography (CT) and magnetic resonance imaging (MRI) may also be used to evaluate the heart valves and arteries. Myocardial PET scans may be performed on certain patients to evaluate blood flow to the heart muscle.

The exercise stress test measures heart rate, blood pressure, and electrocardiographic changes while a patient is performing physically, usually walking on a treadmill. It can help determine heart failure symptoms. Doctors also use exercise tests to evaluate long-term outlook and the effects of particular treatments. A stress test may be done using echocardiography or may be done with nuclear imaging (called myocardial perfusion imaging).

Treatment

Heart failure is classified into four stages (Stage A through Stage D) that reflect the development and progression of the condition. Treatment depends on the stage of heart failure.

Stage A indicates that a patient is at high risk for developing it. In Stage B, the patient has had damage to the heart (for example, from a heart attack), but no symptoms of heart failure. In Stage C, heart failure symptoms manifest.

Stage D is advanced heart failure accompanied by symptoms that may be difficult to manage with standard drug treatments and may require more technologically complex care (defibrillators, mechanical pumps, heart transplantation). The American Heart Association (AHA) emphasizes the importance of a patient-centered approach to treatment decisions. People with advanced heart failure should have ongoing honest discussions with their health care providers concerning their personal preferences and quality of life goals.

Stage A

In Stage A, people are at high risk for heart failure, but do not show any symptoms or have any structural damage of the heart. The first step in managing or preventing heart failure is to treat the primary conditions that cause or complicate heart failure. Risk factors include high blood pressure, heart diseases, diabetes, obesity, metabolic syndrome, and previous use of medications that damage the heart (such as some chemotherapy).

Important risk factors to manage include:

Stage B

Patients have a structural heart abnormality -- seen on echocardiogram or other imaging tests -- but no symptoms of heart failure. Abnormalities include left ventricular hypertrophy and low EF, asymptomatic valvular heart disease, and a previous heart attack. In addition to the treatment guidelines for Stage A, the following types of drugs and devices may be recommended:

Stage C

Patients have a structural abnormality and current or previous symptoms of heart failure, including shortness of breath, fatigue, and difficulty exercising. Treatment includes those for Stage A and B plus:

Stage D

Patients have end-stage symptoms that do not respond to standard pharmacological treatments. Treatment focuses not only on survival, but on symptom relief and quality of life issues. Treatment includes appropriate measures used for Stages A, B, and C plus:

Whenever heart failure worsens, whether quickly or chronically over time, various factors must be considered as the cause:

Medications

Many different medications are used in the treatment of heart failure. They include:

ACE inhibitors are among the most important drugs for treating people with heart failure. ACE inhibitors open blood vessels and decrease the workload of the heart. They are used to treat high blood pressure but can also help improve heart and lung muscle function. ACE inhibitors are particularly important for people with diabetes, because they also help slow the progression of kidney disease.

Brands and Indications

ACE inhibitors are used to treat Stage A high-risk conditions such as high blood pressure, coronary heart disease, and diabetes. They are also used to treat Stage B patients who have had a heart attack or who have left ventricular systolic dysfunction (low ejection fraction), and Stage C patients with heart failure. Specific brands of ACE inhibitors include:

Side Effects of ACE Inhibitors:

ARBs, also known as angiotensin II receptor antagonists, are similar to ACE inhibitors in their ability to open blood vessels and lower blood pressure. They may have fewer or less-severe side effects than ACE inhibitors, especially coughing, and are sometimes prescribed as an alternative to ACE inhibitors.

Brands and Indications

ARBs are used to treat Stage A high-risk conditions such as high blood pressure and coronary artery disease. They are also used to treat Stage B patients who have had a heart attack or who have left ventricular systolic dysfunction (low ejection fraction), and Stage C patients with heart failure. Specific brands include:

Common Side Effects

Beta blockers are almost always used in combination with other drugs, such as ACE inhibitors and diuretics. They help slow heart rate and lower blood pressure. They are used even when abnormally fast heart rhythms (such as atrial fibrillation) are not present and when used properly, beta blockers can reduce the risk of death or rehospitalization. Over time, an EF that is low may increase with beta blocker therapy.

Brands and Indications

Beta blockers treat high blood pressure in Stage A heart failure. They also treat hypertension in Stage B heart failure patients, both those who have had a heart attack and those who have not had a heart attack, but who have heart damage. A specialist should monitor patients with heart failure who take beta blockers. The three beta blockers that are best for treating hypertension in Stage C patients with heart failure are:

Beta Blocker Concerns

Common Side Effects

Check with your doctor about any side effects. DO NOT stop taking these drugs on your own.

Diuretics cause the kidneys to rid the body of excess salt and water. Fluid retention is a major symptom of heart failure. Aggressive use of diuretics can help eliminate excess body fluids, while reducing hospitalizations and improving exercise capacity. These drugs are also important to help prevent heart failure in people with high blood pressure. In addition, certain diuretics, notably spironolactone (Aldactone, generic), block aldosterone, a hormone involved in heart failure. This drug class is beneficial for people with more severe heart failure (Stages C and D).

Diuretics come in many brands and are generally inexpensive. Some need to be taken once a day, some more often a day. Diuretics are usually started at a low dose and gradually increased. Your doctor may advise you to adjust the amount and timing of the diuretic if you notice swelling or weight gain. Diuretics are virtually always used in combination with other drugs, especially ACE inhibitors and beta blockers.

There are three main types of diuretics:

Side Effects

In addition to increased urination, all types of diuretics may cause dry mouth, dehydration, fatigue, muscle cramps, and dizziness and lightheadedness. Diuretics can increase the amount of uric acid in the blood, which can lead to gout.

Potassium imbalances are an important concern with diuretics:

Aldosterone is a hormone that is critical in controlling the body's balance of salt and water. Excessive levels play important roles in high blood pressure and heart failure. Drugs that block aldosterone are prescribed for some people with symptomatic heart failure. They reduce death rates for people with heart failure and coronary artery disease, especially after a heart attack.

Aldosterone blocker brands include spironolactone (Aldactone, generic) and eplerenone (Inspra, generic).

Like loop and thiazide diuretics, aldosterone blockers can cause abnormally high levels of potassium in the blood. It is uncommon for people to need to take potassium supplements at the same time as this drug and may need to avoid foods with high potassium content.

Digitalis is derived from the foxglove plant. It has been used to treat heart disease since the 1700s. Digoxin (Lanoxin, generic) is the most commonly prescribed digitalis preparation. Digoxin can make the heart beat more strongly, decreases heart size and reduce certain heart rhythm disturbances (arrhythmias).

Although it was once a mainstay of heart failure treatment, it is now used less often than newer drugs and is generally reserved for select patients who have significant symptoms while on maximal medical therapy.

While digitalis is generally a safe drug, it can have severe adverse side effects. The most serious side effects are caused by overdose and includes serious arrhythmias.

Hydralazine and nitrates are two older drugs that help relax arteries and veins, thereby reducing the workload of the heart and allowing more blood to reach the tissues. They are used primarily for people who are unable to tolerate ACE inhibitors and angiotensin receptor blockers. BiDil is a drug that combines isosorbide dinitrate and hydralazine. BiDil is approved to specifically treat heart failure in African-American patients while on other standard medications (such as beta blockers and ACE inhibitors).

Statins are important drugs used to lower cholesterol. Statins can help prevent coronary heart disease, which is a leading cause of heart failure. They can also help slow the progression to heart failure for people who have had heart attack or acute coronary syndrome.

These drugs include lovastatin (Mevacor, generic), pravastatin (Pravachol, generic), simvastatin (Zocor, generic), fluvastatin (Lescol), atorvastatin (Lipitor, generic), rosuvastatin (Crestor), and pitavastatin (Livalo). Atorvastatin is specifically approved to reduce the risks for hospitalization for heart failure in people with coronary heart disease.

Antiplatelet and anticoagulant drugs help thin the blood and prevent the formation of blood clots. It is not clear if these drugs are helpful for patients with heart failure who are not at risk for blood clots. These drugs increase the risk for bleeding.

Aspirin

Aspirin is an anti-platelet drug and a type of nonsteroid anti-inflammatory drug (NSAID). Aspirin is recommended for protecting people with (primarily atherosclerotic) heart disease, and can safely be used with ACE inhibitors, particularly when it is taken in lower dosages (75 to 81 mg).

Anticoagulants

Anticoagulants may be appropriate for patients with heart failure and atrial fibrillation to reduce the risk of stroke. Anticoagulants include warfarin (Coumadin, generic), dabigatran (Pradaxa), apixaban (Eliquis), edoxaban (Savaysa), and rivaroxaban (Xarelto).

Sacubitril-Valsartan

Sacubitril-valsartan (Entresto) is a combination angiotensin receptor-neprilysin inhibitor which is usually started in people with severe systolic heart failure to replace an ACE inhibitor or an ARB.

Ivabradine

Ivabradine (Corlanor) is a medication which slows the heart rate and can be useful in some heart failure patients with a heart rate over 70 beats per minute on a beta blocker or who cannot be on a beta blocker.

Erythropoietin

Erythropoietin is used to treat anemia, which is a common complication of heart failure. This drug can increase the risk of blood clots and stroke. Due to these risks, recent guidelines recommend against the use of erythropoietin drugs for people with heart failure and mild-to-moderate anemia.

Tolvaptan

Tolvaptan (Samsca) is a drug approved for treating hyponatremia (low sodium levels) associated with heart failure and other conditions.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Dapagliflozin (Farxiga) is the first drug from the family of SGLT2 inhibitors to be approved for use in patients with heart failure with reduced ejection fraction. Dapagliflozin decreased the risk of cardiovascular death and hospitalizations in these patients. Because SGLT2 inhibitors also improve blood sugar levels, they may be especially useful for patients who have both heart failure and type 2 diabetes.

Surgery and Devices

Revascularization helps to restore blood flow to heart affected by coronary artery disease. It can treat blocked arteries in patients with coronary artery disease and angina, and may help select patients with heart failure who have these conditions. Techniques include coronary artery bypass graft (CABG) and angioplasty usually with stenting (also called percutaneous coronary intervention [PCI]).

CABG is a traditional type of open heart surgery. Angioplasty is a less-invasive procedure that uses a catheter to inflate a balloon inside the artery. A metal stent may also be inserted during an angioplasty procedure.

Coronary artery balloon angioplasty - Series

Click the icon to see images of a coronary artery balloon angioplasty.
Normal heart anatomy

Click the icon to see an image of normal heart anatomy.

Pacemakers, also called pacers, help regulate the heart's beating action, especially when the heart beats too slowly. Biventricular pacers (BVPs) are a special type of pacemaker used for patients with heart failure. Because BVPs help the heart's left and right chambers to beat in a more coordinated fashion, this treatment is called cardiac resynchronization therapy (CST).

BVPs are recommended for patients with heart failure that is not controlled with medication therapy and who have evidence of left-bundle branch block on their ECG. Left-bundle branch block is a condition in which the electrical impulses in the heart do not follow their normal pattern, causing the heart to pump inefficiently.

People with enlarged hearts that beat weakly are at risk for having serious cardiac arrhythmias (abnormal heartbeats) that are associated with sudden death. Implantable cardioverter defibrillators (ICDs) can quickly detect life-threatening arrhythmias. The ICD is designed to convert any abnormal heart rhythm back to normal by sending an electrical shock to your heart. This action is called defibrillation or cardioversion. This device can also work as a pacemaker.

People with ICDs need to avoid certain types of electronic devices that can disrupt the device. They may also need to avoid certain types of medical and imaging procedures. It is important to talk with your doctor about any questions you have about living with an ICD. Be sure to let your doctor know if you feel anxious or depressed. It's not uncommon for people with ICDs to experience these emotions, and psychological support is important for both patients and their families.

In recent years, certain ICD models and biventricular pacemaker defibrillators have been recalled by the manufacturers because of circuitry flaws. However, doctors stress that the chance of an ICD or pacemaker saving a person's life far outweigh the possible risks of these devices failing.

Ventricular assist devices (VAD) are mechanical devices that pump blood through the body. They are used as a bridge to transplant for patients who are on medications but still have severe symptoms and are waiting for a donor heart. In some cases, they may delay the need for a transplant. Therefore, they may be used as short-term (less than 1 week) or longer-term support.

Ventricular assist devices include:

The risks and complications involved with many of these devices include bleeding, blood clots, and right-side heart failure. Infections are a particular hazard.

People who suffer from severe heart failure and whose symptoms do not improve with drug therapy or mechanical assistance may be candidates for heart transplantation. About 2,000 heart transplant operations are performed in the United States each year, but thousands more patients wait on a list for a donor heart.

The most important factor for heart transplant eligibility is overall health. Chronological age is less important. Most heart transplant candidates are between the ages of 50 to 64 years.

While the risks of this procedure are high, about 85% of patients survive the first year after receiving a heart transplant, and about 73% survive for 5 years. Survival after 10 years is about 56%. In general, the highest risk factors for death, 3 or more years after a transplant operation are a special kind of coronary artery disease (called transplant vasculopathy) and the adverse effects (infection and certain cancers) of immunosuppressive drugs used in the procedure.

Artificial hearts are implantable devices that serve as replacements for the heart's failing valves. There are several types of artificial hearts. The SynCardia Total Artificial Heart is used to help sustain patients who are waiting for a heart transplant. AbioCor is a permanent implantable artificial heart. It is available only for patients who are not eligible for a heart transplant and who are not expected to live more than a month without medical treatment. Both of these devices are very expensive, require complex surgery, and only extend survival by a few months. People need to have a chest cavity large enough to contain the device. New artificial heart systems are being developed and tested.

Lifestyle Changes

Up to half of patients hospitalized for heart failure are back in the hospital within 6 months. Many people return because of lifestyle factors, such as poor diet, failure to comply with medications, and social isolation.

Programs that offer intensive follow-up to ensure that the patient complies with lifestyle changes and medication regimens at home can reduce rehospitalization and improve survival. Patients without available rehabilitation programs should seek support from local and national heart associations and groups. A strong emotional support network is also important.

Medicare recently approved cardiac rehabilitation for some patients with heart failure. Ask your doctor if a program near you may be appropriate.

People should weigh themselves each morning and keep a record. Any changes are important:

Sodium (Salt) Restriction

All patients with heart failure should limit their sodium (salt) intake to less than 2,400 mg a day. (Check with your doctor for exact sodium limits.) DO NOT add salt to cooking and meals, and avoid foods high in sodium. These salty foods include ham, bacon, hot dogs, lunch meats, prepared snack foods, dry cereal, cheese, canned soups, soy sauce, and condiments. Some people may need to reduce the amount of water they consume. People with high cholesterol levels or diabetes require additional dietary precautions.

Here are some tips to lower your salt and sodium intake:

People with heart failure used to be discouraged from exercising. Now, doctors think that exercise, when performed under medical supervision, is extremely important for stable patients. The AHA recommends exercise (or regular physical activity) as safe and effective for patients with heart failure who are able to participate. Studies have reported that patients with stable conditions who engage in regular moderate exercise (three times a week) have a better quality of life and lower mortality rates than those who do not exercise. However:

Studies report benefits from specific exercises:

Some people with severe heart failure need periods of bed rest. To reduce congestion in the lungs, the patient's upper body should be elevated. For most patients, resting in an armchair is better than lying in bed. Relaxing and contracting leg muscles are important to prevent clots. As the patient improves, a doctor will progressively recommend more activity.

Stress reduction techniques, such as meditation and relaxation response methods, may have direct physical benefits. Anxiety can cause the heart to work harder and beat faster.

The goal of palliative care is to help the patient with a serious illness feel better. It prevents or treats symptoms and side effects of disease and treatments.

Palliative care can help treat symptoms such as pain, shortness of breath, trouble sleeping, and loss of appetite. Palliative care also treats emotional, social, practical, and spiritual problems that illness brings up. When the patient feels better in these areas, they have an improved quality of life.

Palliative care can be given at the same time as treatments meant to cure or treat the disease. You may get palliative care when heart failure is diagnosed, throughout treatment, during follow-up, and at the end of life.

Any provider can give palliative care, but some specialize in it. Palliative care may be given by a team of doctors, nurses, registered dietitians, social workers, psychologists, massage therapists, and chaplains. It may be offered by hospitals, home health agencies, or long-term care facilities.

Both palliative care and hospice care provide comfort:

Patients with heart failure may seek alternative remedies. Despite various claims, there is generally no strong evidence to support their effectiveness. Some herbs and dietary supplements can pose specific risks for patients with heart failure:

Generally, manufacturers of herbal remedies and dietary supplements do not need FDA approval to sell their products. Just like a drug, herbs and supplements can affect the body's chemistry, and therefore have the potential to produce side effects that may be harmful. There have been several reported cases of serious and even lethal side effects from herbal products. Always check with your doctor before using any herbal remedies or dietary supplements.

Resources

References

Abraham WT. Devices for monitoring and managing heart failure. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 11th ed. Philadelphia, PA: Elsevier; 2019:chap 27.

Allen LA, Stevenson LW, Grady KL, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012;125(15):1928-1952. PMID: 22392529 pubmed.ncbi.nlm.nih.gov/22392529/.

American Academy of Family Physicians; American Academy of Hospice and Palliative Medicine; American Nurses Association, et al. ACCF/AHA/AMA-PCPI 2011 performance measures for adults with heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association - Physician Consortium for Performance Improvement. J Am Coll Cardiol. 2012;59(20):1812-1832. PMID: 22534627 pubmed.ncbi.nlm.nih.gov/22534627/.

Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646. PMID: 30879355 pubmed.ncbi.nlm.nih.gov/30879355/.

Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(11):1505-1535. PMID: 29806100 pubmed.ncbi.nlm.nih.gov/29806100/.

Dobre D, Borer JS, Fox K, et al. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. Eur J Heart Fail. 2014;16(1):76-85. PMID: 23928650 pubmed.ncbi.nlm.nih.gov/23928650/.

Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC Guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2960-2984. PMID: 24239922 pubmed.ncbi.nlm.nih.gov/24239922/.

Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013;61(3):e6-e75. PMID: 23265327 pubmed.ncbi.nlm.nih.gov/23265327/.

Forman DE, Sanderson BK, Josephson RA, Raikhelkar J, Bittner V; American College of Cardiology's Prevention of Cardiovascular Disease Section. Heart failure as a newly approved diagnosis for cardiac rehabilitation: challenges and opportunities. J Am Coll Cardiol. 2015;65(24):2652-2659. PMID: 26088305 pubmed.ncbi.nlm.nih.gov/26088305/.

Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-1356. PMID: 32483830 pubmed.ncbi.nlm.nih.gov/32483830/.

Goldenberg I, Kutyifa V, Klein HU, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med. 2014;370(18):1694-1701. PMID: 24678999 pubmed.ncbi.nlm.nih.gov/24678999/.

Januzzi JL, Mann DL. Approach to the patient with heart failure. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 11th ed. Philadelphia, PA: Elsevier; 2019:chap 21.

Jessup M, Atluri P, Acker MA. Surgical management of heart failure. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 11th ed. Philadelphia, PA: Elsevier; 2019:chap 28.

Kirklin JK, Pagani FD, Goldstein DJ, et al. American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support. J Thorac Cardiovasc Surg. 2020;159(3):865-896. PMID: 31983522 pubmed.ncbi.nlm.nih.gov/31983522/.

Madmani ME, Yusuf Solaiman A, Tamr Agha K, et al. Coenzyme Q10 for heart failure. Cochrane Database Syst Rev. 2014;(6):CD008684. PMID: 24049047 pubmed.ncbi.nlm.nih.gov/24049047/.

Mann DL. Management of patients with heart failure with reduced ejection fraction. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 11th ed. Philadelphia, PA: Elsevier; 2019:chap 25.

McMurray JJ, Packer M, Desai AS, Gong J, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. PMID: 25176015 pubmed.ncbi.nlm.nih.gov/25176015/.

Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart Failure With Reduced Ejection Fraction: A Review. JAMA. 2020;324(5):488-504. PMID: 32749493 pubmed.ncbi.nlm.nih.gov/32749493/.

Nguyen PK, Rhee JW, Wu JC. Adult stem cell therapy and heart failure, 2000 to 2016: a systematic Review. JAMA Cardiol. 2016;1(7):831-841. PMID: 27557438 pubmed.ncbi.nlm.nih.gov/27557438/.

Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54-61. PMID: 25403646 pubmed.ncbi.nlm.nih.gov/25403646/.

Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and the heart. Circulation. 2014;129(8):907-916. PMID: 24566065 pubmed.ncbi.nlm.nih.gov/24566065/.

Qaseem A, Humphrey LL, Fitterman N, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;159(11):770-779. PMID: 24297193 pubmed.ncbi.nlm.nih.gov/24297193/.

Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. Lancet. 2019;393(10175):1034-1044. PMID: 30860029 pubmed.ncbi.nlm.nih.gov/30860029/.

Russo AM, Stainback RF, Bailey SR, Epstein AE, Heidenreich PA, Jessup M, Kapa S, Kremers MS, Lindsay BD, Stevenson LW. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Heart Rhythm. 2013;10(4):e11-58. PMID: 23473952 pubmed.ncbi.nlm.nih.gov/30860029/.

da Silva RMFL, Borges ASR, Silva NP, et al. How heart rate should be controlled in patients with atherosclerosis and heart failure. Curr Atheroscler Rep. 2018;20(11):54. PMID: 30225613 pubmed.ncbi.nlm.nih.gov/30225613/.

Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374(16):1511-1520. PMID: 27040723 pubmed.ncbi.nlm.nih.gov/27040723/.

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248. PMID: 29146535 pubmed.ncbi.nlm.nih.gov/29146535/.

Wolk MJ, Bailey SR, Doherty JU, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014;63(4):380-406. PMID: 24355759 pubmed.ncbi.nlm.nih.gov/24355759/.

Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327. PMID: 23741058 pubmed.ncbi.nlm.nih.gov/23741058/.

Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829. PMID: 32877652. pubmed.ncbi.nlm.nih.gov/32877652/.

Review Date: 1/16/2021
Reviewed By: Thomas S. Metkus, MD, Assistant Professor of Medicine and Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, timeliness, or correctness of any translations made by a third-party service of the information provided herein into any other language. © 1997- A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
© 1997- adam.comAll rights reserved.
A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.